This article is more than 5 years old. Information may no longer be current.
AbbVie and Amgen announce settlement of adalimumab patent dispute
Click Here to Manage Email Alerts
AbbVie and Amgen announced a global settlement to resolve all intellectual property-related litigation with regard to Amgen’s proposed biosimilar to adalimumab.
With the agreement, AbbVie will grant Amgen a non-exclusive license to its intellectual property for Humira (adalimumab), with the license period beginning in the United States on Jan. 31, 2023 for the adalimumab biosimilar, Amjevita, and on Oct. 16, 2018 in most countries in the European Union for the adalimumab biosimilar, Amgevita.
According to a press release, neither company disclosed financial terms of the agreement.
“We are pleased to have reached this settlement with Amgen which respects the breadth and strength of our intellectual property portfolio,” Laura Schumacher, executive vice president of external affairs, general counsel and corporate secretary for AbbVie, said in a release. “As an innovation-driven bio-pharmaceutical company, we believe intellectual property is essential to protect the investment in science and advance novel cures for the toughest health challenges. In reaching this agreement, we have achieved the balance between protecting investment in innovation and providing access to biosimilars, which will play an important role in our health care system. We will continue to defend our intellectual property and to reinvest in further advancements in medicine to bring choices to patients in need.”
“We look forward to leveraging our existing biologics capabilities to bring high-quality biosimilars to patients worldwide,” Scott Foraker, vice president and general manager of biosimilars at Amgen, said in a press release. “Amgevita will be one of our first biosimilar launches, and this agreement will allow us to secure a strong foothold in the $4 billion European adalimumab market. Building on our strong inflammatory disease presence in the United States, we are excited to develop our inflammation capabilities in Europe, extending our reach and helping more patients gain access to this important class of therapies.”
References: